OCT is now beginning a phase I study of a drug for tuberculosis
It is an open-label prospective study of safety, tolerability, pharmacokinetics and food effect on the drug when used in increasing doses.
Patient enrollment will begin at the end of June. The participants of the study will include healthy male and female volunteers, ages 18-45.
Currently, the global medical community recognizes the urgent demand to create new anti-tuberculosis drugs and develop new modes of etiotropic treatment of tuberculosis.
In this trial, OCT will be responsible for different study-related activities, including project management, clinical monitoring, logistics, quality assurance and final report preparation.Back to the list